Miracell selected as one of the “1000 Innovative Companies”
Stem cell company Miracell has been selected as one of the government’s “1,000 Leading Innovative Companies.”
Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected for the third round of the “1,000 Leading Innovative Companies” program, announced by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare.
The “1,000 Leading Innovative Companies” program, comprised of nine ministries including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Oceans and Fisheries, selects leading innovative companies by industry and provides them with exceptional financial support to foster them as future core companies. Launched on July 30, 2020,
the program was approved at the 12th meeting of the Central Economic Response Headquarters.
Starting with 32 companies in the first round, 247 were selected in the second round, and 321 companies were selected this time. The Financial Services Commission plans to select 1,000+ representative innovative companies from each industry by 2022.
Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical devices, and innovative pharmaceuticals categories, based on selection criteria established by the Ministry of Health and Welfare.
Launched in 2009 with the introduction of Harvard University’s cell extraction technology, Miracell successfully developed a “Minimally Manipulated Stem Cell Isolation and Amplification Source Technology” in 2017. The Ministry of SMEs and Startups selected this technology for a small business commercialization technology development project.
Based on this technology, Miracell successfully developed and domestically produced SmartPReP2, a kit developed by the Harvard Medical School’s Immunology Research Institute in 2018 and exported globally, and SMART M-CELL2, a replacement kit.
Test results from Seoul National University Bundang Hospital showed that its performance was comparable to or even superior to SmartPReP2.
Smart Mcell 2 is a device that extracts large quantities of automatically separated stem cells from bone marrow blood extracted from the body through centrifugation. It is currently used in major hospitals both domestically and internationally.
CEO Shin Hyun-soon stated, “Being selected as a National Representative Innovative Company is very significant. It opens up new avenues for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.”
CEO Shin continued, “Stem cell therapy involves extracting bone marrow blood from the patient, concentrating it through centrifugation, extracting a large quantity of stem cells, and then reinjecting them into the body. Because old cells regenerate into healthy ones, it is highly effective in improving bodily functions.”
Recognized as an innovative technology, Smart Mcell 2 is a cutting-edge system for “bone marrow and blood stem cell manufacturing,” using biological pharmaceutical manufacturing technology to extract hematopoietic stem cells (CD34+) from blood and mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be isolated and extracted in one session,
within an hour, and cell viability rates reach a remarkable 80-98%.
Its automated system features a closed, air-tight system that prevents cell deformation.
Smart Mcell 2 is equipped with special LEDs to enhance cell activity, converting the existing analog system to digital, and even features voice support, making it a perfect fit for cutting-edge bio-healthcare medical devices.
Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, our biological pharmaceutical manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology that helps treat conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. We also have secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, and 22 patent applications for cell extraction technology.